INTRODUCTION
Cornelia de Lange syndrome (CdLS; MIM#s 122470, 300590, 610759, 614701, 300882 ) is a multisystem developmental diagnosis characterized by distinctive facial dysmorphism, pre-and postnatal growth failure, intellectual disability, limb malformations, hypertrichosis and variable involvement of other organ systems . The prevalence is estimated to be up to 1 in 15,000 births . Almost all cases are sporadic with de novo heterozygous loss-of-function (LOF) mutations in NIPBL (MIM# 608667) being the most common genetic finding in typical CdLS Tonkin, et al., 2004; Wierzba, et al., 2012) . A proportion of the "NIPBL-negative" cases with typical CdLS have recently been shown to have mosaic NIPBL mutations, often undetected in the blood by Sanger based screening Baquero-Montoya, et al., 2014; Huisman, et al., 2013) . Mutations in four other genes have been reported to account for a smaller proportion of mostly atypical cases; SMC1A (MIM# 300040) on chromosome Xp11 (~4-6%), SMC3 (MIM# 606062) on chromosome 10q25 (<1%), RAD21 (MIM# 606462) on chromosome 8q24 (<1%), and HDAC8 (MIM# 300269) on chromosome Xq13 (4%) (Deardorff, et al., 2012a; Deardorff, et al., 2007; Deardorff, et al., 2012b; Kaiser, et al., 2014; Minor, et al., 2014; Musio, et al., 2006) . These five genes encode regulatory or structural components of the evolutionary conserved cohesin complex, which has been implicated in a wide range of functions including sister chromatid cohesion, DNA repair mechanisms, gene regulation and maintenance of genome stability (Revenkova, et al., 2009) . Cohesin is a multimeric complex consisting of an SMC1A -SMC3 heterodimer and the two non-SMC subunits, RAD21 and a STAG protein. Each SMC protein folds upon itself so that the N-and C-termini meet to form a globular ATP-binding "head" domain separated from a globular "hinge" domain by antiparallel coiled-coil segments. SMC3 and SMC1A interact via their respective hinge regions to form a bracelet-shaped heterodimer ( Figure 1A ). The two ATPase head domains further interact with the N-and C-termini of RAD21, creating a ring structure that is proposed to encircle sister chromatids (Nasmyth and Haering, 2009) . NIPBL has been shown to facilitate loading of cohesin onto chromatin, and HDAC8 is involved in recycling of cohesin after its removal from chromatin (Deardorff, et al., 2012a) .
To date, only the clinical features of the unique mildly affected CdLS male with SMC3 mutation has been published (c.1464_1466del, p.(Glu488del)) (Deardorff, et al., 2007; . Subsequently, a missense SMC3 mutation has been reported without clinical correlation in one patient within a large cohort of individuals with autism spectrum disorder (c.2413C>T; p.(Arg805Cys)) (Sanders, et al., 2012) and five additional mutations in a cohort of typical and atypical CdLS patients with the detailed clinical descriptions of these cases documented for the first time in this manuscript.
Here, we report the clinical features of 16 unrelated SMC3 individuals identified via a large international collaboration and assess the degree of overlap with typical CdLS associated with this gene. Of these, ten are unreported patients with novel or reported mutations in the SMC3 gene and six individuals have only had molecular information previously published. Furthermore, we mapped all mutations to the known structure of the SMC complex to predict molecular/functional consequences. Our results clearly indicate that SMC3 mutations result in a CdLS-like phenotype and account for a higher percentage of CdLS and CdLS-like cases than previously appreciated.
MATERIALS AND METHODS

Patient Recruitment
We screened for mutations in SMC3 an internationally assembled cohort of 674 patients with typical CdLS and overlapping clinical presentations who had no known molecular etiology. All patients were enrolled in this study under institutionally-approved protocols of informed consent at the Odense University Hospital, University Hospital 
Mutation screening by Sanger sequencing
Genomic DNA was isolated from peripheral blood leukocytes using standard protocols. PCR primers flanking the entire coding region (exons 1-29) and flanking intron sequences of SMC3 gene were used as previously described (Deardorff, et al., 2007; . The resulting PCR products were sequenced using the BigDye Terminator 3.1 reagents on an ABI 3730 analyzer. The SMC3 reference sequence used was NM_005445.3, in which the A of the ATG translation initiation codon was nucleotide 1. Parental genotypes were screened to assess whether the variant was de novo or inherited when parental DNA was available.
Ion Torrent Semiconductor gene panel sequencing
Mutation analyses by Ion AmpliSeq-Ion PGM were performed as described previously Baquero-Montoya, et al., 2014; .
Briefly, 10-20 ng of genomic DNA was amplified using custom-designed gene panels (Ion AmpliSeq™, Life Technologies) to cover the coding exons of the known CdLS genes, including approximately 90% of the coding sequence of SMC3 (NC_000010) and its splice junctions in particular. The DNA library was sequenced on an Ion PGM™ instrument (Life Technologies). Sequence alignment and variant calling were performed as described previously Baquero-Montoya, et al., 2014; .
Possible pathological variants found were assessed by Sanger sequencing.
Exome sequencing
For P7, exomes were captured with the Agilent SureSelect Human All Exon V4+UTR kit (Agilent Technologies, Santa Clara, CA, USA) and sequencing was performed on Illumina HiSeq 2000 machines using standard pair-end read sequencing protocol (Illumina, San Diego, CA, USA). Analysis was as per (Falk, et al., 2014; . Possible pathological variants found were confirmed by Sanger sequencing.
Exome sequencing for P13 was performed clinically at the Baylor Whole Genome Lab.
Briefly, exomes were captured using VCRome 2.1 in-solution capture, and sequenced on Illumina HiSeq using 100bp paired end reads. Data analysis and interpretation was as per (Yang, et al., 2013) . Possible pathological variants found were confirmed by Sanger sequencing.
Exome sequencing was performed in the affected individual P14 as well as in the nonaffected parents. Exomes were enriched in solution with SureSelect XT Target Enrichment System (Agilent Technologies) or SeqCap EZ VCRome 2.0 (Roche NimbleGen) and sequenced as 100 bp paired-end runs on a HISeq2000 or HISeq 2500 system (Illumina).
Mutation modelling
Three dimensional models of the HEAD and HINGE domains of the human SMC1A/SMC3 dimer, for wild-type (wt) and mutant proteins, were generated using homology modelling procedures and the coordinates of the mouse HINGE domain ( (Kurze, et al., 2011) ; PDB code: 2WD5) and yeast HEAD domain -SMC1 homodimer-( (Haering, et al., 2004) ; PDB code: 1W1W) as templates. Model coordinates were built using the SWISS-MODEL server (Guex, et al., 1999; Peitsch, 1996; Schwede, et al., 2003) available at http://swissmodel.expasy.org/, and their structural quality was checked using the analysis programs provided by the same server (Anolea/Gromos/QMEAN4; (Benkert, et al., 2011)) being within the range of those accepted for homology-based structure models. To optimize geometries, models were energy minimized using the GROMOS 43B1 force field implemented in DeepView (http://spdbv.vital-it.ch/), using 500 steps of steepest descent minimization followed by 500 steps of conjugate-gradient minimization. Coiled-coil predictions were calculated using COILS server with a window of 28 residues (http://www.ch.embnet.org; (Lupas, et al., 1991) ). Multiple sequence alignment of proteins from the SMC3 family was generated using TCOFFEE (http://www.tcoffee.org/) (Notredame, et al., 2000) . Functional prediction for nonsynonymous or indel variants were obtained using PolyPhen-2 (http://genetics.bwh.harvard.edu/pph/) (Adzhubei, et al., 2010) , SIFT (http://sift.jcvi.org/) (Ng and Henikoff, 2001 ), PROVEAN (http://provean.jcvi.org/index.php) (Choi, et al., 2012) , Mutation Taster (http://www.mutationtaster.org/) (Schwarz, et al., 2010) 
RESULTS
Intragenic mutations in SMC3 in a large cohort of patients
Sequence analysis of patients with CdLS and CdLS-like phenotypes for mutations in SMC3 identified 15 different intragenic mutations in 16 unrelated individuals. Six of 15 mutations have been previously described Deardorff, et al., 2007) , therefore here we report ten individuals with nine new mutations ( Table 1) . Seven of the ten individuals had both parents available for testing and in each case these mutations occurred de novo. One in-frame de novo deletion of three nucleotides (c.1464_1466del; p.(Glu488del)) was also identified in the first reported individual (Deardorff, et al., 2007) .
Three of these are caused by in-frame mutations that retain the open reading frame (one duplication and two deletions of one or two residues) and seven mutations were missense (Table 1 , Figure 1 , Supp. Figure S1 ). All variants have been added to a publicly accessible LOVD database (http://www.LOVD.nl/SMC3). None of these mutations were seen in 100 control alleles or publicly available repositories of sequence variation.
In silico Analyses of Missense and In-frame Mutations
The predicted functional effect of each mutation is summarized in Table 1 and the cross-species alignment showing the degree of evolutionary conservation of the residues involved in the missense and in-frame variants is shown in Figure 1B . Figure 1A indicates the location of each variant with regard to the known functional domains of SMC3.
Gly655 localizes to the SMC3 hinge domain and the substitution with aspartic acid is predicted to structurally destabilize the domain core. Thr235, Arg236, Arg839 and His917 localize to the N-and the C-terminal coiled-coil structures respectively and their deletion or substitution is predicted to displace the two antiparallel helices (Supp. Figure S2 ).
In the globular ATP-binding head domain Phe47 is located in the alpha helices.
Gln1147 is within the functional motif D-loop, close to both the gamma-phosphate of ATP and the interface between the head domains of SMC3 and SMC1A. Substitution of this polar residue Gln1147 by a negatively charged glutamate residue could alter the ATPase activity of the active site of the heterodimer as well as alter the essential interaction between SMC1A
and SMC3 at the head interface ( Figure 1C ). Thr1215 is located in an apparently nonstructured region close to the C-terminus and the effect of the isoleucine substitution at this residue is not clear, although it cannot be excluded a putative role in the SMC3-RAD21
interaction.
Clinical features of individuals with SMC3 mutations
The clinical features in the 16 individuals with mutations involving SMC3 are summarized in Table 2 and Supp. Table S1 . Figure 2 shows facial and limb findings. Many patients have CdLS-like craniofacial features including brachycephaly (73%, (11/15)), low anterior hairline (50%, (7/14)), arched eyebrows (93%, (14/15)), synophrys (73%, (11/15)), long eyelashes (94%, (15/16)), ptosis (27%, (4/15)), depressed nasal bridge (47%, (7/15)), anteverted nostrils (57%, (8/14)), long philtrum (67%, (10/15)), thin upper lip vermilion (81%, (13/16)), downturned corners of the mouth (60%, (9/15)), high palate (45%, (5/11)), dental anomalies (38%, (5/13)) and micrognathia (40%, (6/15)) ( Table 2) . Although often long, the philtrum is typically not smooth in these individuals and only one patient had a cleft palate. Major limb malformations were not observed. Intellectual disability was a prominent feature, although behavioral problems were not frequently reported and many were described as having friendly personalities.
DISCUSSION
To further characterize the nature of SMC3 gene mutations and the range of resulting clinical features, we utilized an international cooperative research and clinical effort coupled with standard sequencing and Next Generation Sequencing (NGS) strategies. This enabled us to identify 16 probands with 15 different intragenic mutations in SMC3, including the previously reported individuals Deardorff, et al., 2007) . Based on these numbers, we could estimate that individuals with SMC3 mutations comprise approximately ~1-2% of patients with features suggestive of CdLS or overlapping phenotypes.
Typically, SMC3 mutations identified in these CdLS-like patients are missense or inframe insertions or deletions, similar to CdLS-causing mutations found in the SMC1A protein (Deardorff, et al., 2007; Gimigliano, et al., 2012; Liu, et al., 2009; Mannini, et al., 2010; Musio, et al., 2006; Revenkova, et al., 2009 ). Nine of fifteen SMC3 mutations identified predict amino acid alterations in the coiled-coil domain ( Figure 1A , Supp. Figure   S2 ). In the SMC1A-associated CdLS-like disorder, 69% of the disease causing mutations (all missense/in-frame) are also identified in the cognate coiled-coil domain (Gervasini, et al., 2013) . The similarity of structure and function of the two SMC proteins, as well as the mutation spectrum, suggests that SMC3 missense/in-frame mutations may act via a dominant negative effect as has been previously suggested for other mutations in the SMC1A protein (Deardorff, et al., 2007; Mannini, et al., 2013) .
Several craniofacial features commonly seen in typical CdLS (>80% of the CdLS patients, reviewed in ) are absent or infrequent in this SMC3 cohort. For example, while the eyebrows may be highly arched and the eyelashes long, synophrys is often absent or subtle. The nasal bridge is less frequently depressed, and the nasal tip is often broad or bulbous, unlike the small triangular shaped nose in typical CdLS. Furthermore, the nostrils are not typically anteverted in this cohort, as is seen in CdLS caused by mutations in NIPBL (Rohatgi, et al., 2010) . The philtrum may be long but is often well formed in this cohort and infrequently flat, as in typical CdLS. Thin upper lips vermilion are observed but the downturned mouth often seen in typical CdLS is uncommon.
Congenital heart defects (CHD) are common in CdLS (13-70%) with isolated defects seen in 86% (PS, VSD and ASD) and multiple defects in 14% ).
Consistent with this, SMC3 probands appear to have cardiac malformations (56%). For example a number of individuals presented with some degree of pulmonic stenosis, one of the most frequent findings in CdLS ). In addition, two individuals showed with aortic stenosis with bicuspid aortic valve and one with
Tetralogy of Fallot. While this frequency and severity of cardiac anomalies can be seen in CdLS caused by mutations in NIPBL, they are infrequent in patients with SMC1A mutations , suggesting that SMC3 is important for the normal development of the heart.
Clinical comparison between two individuals (P6 and P7) which carried the same deletion of three nucleotides, c.1464_1466del (Deardorff, et al., 2007) , showed a similar craniofacial appearance during their newborn period, even though this evolved with time differently (Figure 2 ). In addition, these patients had markedly different cognitive and developmental impairment and musculoskeletal involvement, with one working as an adult and the other nonverbal and nonambulatory (Figure 2 , Supp. Table S1 ). This emphasizes that, phenotypes associated with the identical mutations are likely variable, which indicates the influence of other factors in the manifestation of CdLS, as it has been reported for other
CdLS genes .
In general, SMC3 probands present with a mild to severe phenotype that differs from typical CdLS that is frequently caused by NIPBL mutations. Clinical features of patients with SMC3-mutations are more similar to those of patients with mutations in SMC1A (Borck, et al., 2007; Deardorff, et al., 2007; Gervasini, et al., 2013; Liu, et al., 2009; Mannini, et al., 2010; Musio, et al., 2006) . Thus the craniofacial phenotype of patients with mutations in SMC1A and SMC3 genes do show overlapping features such as broader, fuller less arched eyebrows and a more prominent nasal bridge (Deardorff, et al., 2007; Rohatgi, et al., 2010) .
In addition, both groups of patients seem to have less growth restriction than typically seen in patients with mutations in NIPBL. However, this is fairly difficult to generalize, given the variability in the range of severity and the small number of patients with SMC3 mutations.
Interestingly, several individuals from this cohort were ascertained independently of a diagnosis of CdLS (e.g. P7 and P13). Although they have some CdLS-overlapping features, they were felt to be divergent enough from CdLS to pursue exome-based testing rather than CdLS gene panel testing. In addition, an SMC3 mutation has been reported in a patient with autism spectrum disorder, but to our knowledge has no obvious CdLS phenotype (Sanders, et al., 2012) . These findings are consistent with an emerging range of clinical phenotypes caused by mutations in the cohesin complex, as is supported by the finding of an HDAC8 mutation in a family with Wilson-Turner syndrome (intellectual disability, truncal obesity, hypogonadism and distinctive facial features) (Harakalova, et al., 2012) and an SGOL1 mutation in 17 patients with CAID syndrome (Chronic Atrial and Intestinal Dysrhythmia) (Chetaille, et al., 2014) . These findings indicate that the range of clinical phenotypes caused by alterations in cohesin may be significantly broader than previously appreciated.
In conclusion, we report a series of SMC3 mutations that provide a significant advance in our understanding of the clinical and molecular basis of human disorders of cohesin. Although this cohort represents ~1-2% of individuals with CdLS-like phenotypes, they provide us novel insight into the understanding of cohesin in health and disease.
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Table 1. SMC3 mutations identified
The on-line predicted functional effect of nonsynonymous or indel variants have been determined by SIFT or Provean programs respectively. The SMC3 reference sequence used was NM_005445.3, in which the A of the ATG translation initiation codon was nucleotide 1. 
